Consider This Before Taking a Position in Zimmer Biomet (ZBH)

By Kim Brooks • Wednesday, September 06 16:17 • Permanent Link

With gains of 4.1%, Zimmer Biomet was one of the winners on Wall Street today. Its shares are now trading at $122.67 and have logged a -1.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:

Zimmer Biomet has moved 13.0% over the last year, and the S&P 500 logged a change of 14.0%
ZBH has an average analyst rating of hold and is -18.3% away from its mean target price of $150.15 per share
Its trailing earnings per share (EPS) is $2.4
Zimmer Biomet has a trailing 12 month Price to Earnings (P/E) ratio of 51.1 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $8.04 and its forward P/E ratio is 15.3
The company has a Price to Book (P/B) ratio of 2.07 in contrast to the S&P 500's average ratio of 2.95
Zimmer Biomet is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
ZBH has reported YOY quarterly earnings growth of 37.0% and gross profit margins of 0.7%
The company has a free cash flow of $1.26 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.